Thursday, March 16, 2023 | 2:05 – 2:35 PM ET
The Inflation Reduction Act gave Medicare the authority to negotiate lower prescription drug prices. Yesterday, the Centers for Medicare & Medicaid Services (CMS) issued initial guidance detailing the requirements and parameters — including requests for public comment — on key elements of the new Medicare Drug Price Negotiation Program for 2026, the first year the negotiated prices will apply. The negotiation process will focus on key questions, including but not limited to the selected drug’s clinical benefit, the extent to which it fulfills an unmet medical need, and its impact on people who rely on Medicare. As a result of negotiation, people with Medicare will have access to innovative, life-saving treatments at costs that will be lower for both them and Medicare.
Today, March 16, from 2:05-2:35 PM ET, CMS Administrator Chiquita Brooks-LaSure and Dr. Meena Seshamani, Deputy Administrator and Director, Center for Medicare, will host a call to discuss this initial guidance.
Please register in advance to join the call. After registering, you will receive a confirmation email containing information about joining the call. Please note that when you click the link to join the call on March 16, you will see a message stating that the host will allow you to join the event momentarily. Please continue to wait at that screen until the CMS team begins the call.